Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage

Inclusion Criteria:

• Age of 18 years or older
• A clinical diagnosis of supratentorial intracerebral hemorrhage is confirmed by brainCT scan
• Hematoma volume ≤40ml
• The first dose of statin can be given within 24h of intracerebral hemorrhage symptomonset (if the patient is randomized to statin group)
• Written informed consent

Exclusion Criteria:

• Presence of intraventricular hemorrhage or subarachnoid hemorrhage
• Planned surgical hematoma evacuation by open craniotomy prior to randomization (planned minimally invasive surgery is not a contraindication to enrollment)
• Suspected secondary intracerebral hemorrhage related to trauma, tumor, rupturedaneurysm or arteriovenous malformation, hemorrhagic transformation of an ischemicinfarct, Moyamoya disease, or venous sinus thrombosis
• Unable to swallow a statin pill and have contraindication to position a nasogastrictube
• Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST), or alanine aminotransferase (ALT) ≥2 × the upper limit of normal
• Known pregnancy, or positive pregnancy test, or breastfeeding
• Other diseases or abnormalities that the investigator believed might compromise thepatient's safety during the study
• Historical modified Rankin scale score ≥2
• Life expectancy of less than 7 days
• Participation in another clinical study within 30 days prior to screening for thepresent study
• Prior use of statins within 1 month before intracerebral hemorrhage